Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348814 · ClinicalTrials.gov registry record
Development of a Novel Biomarker for Liver Fibrosis
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 25
- Enrollment target
NCT02348814: Completed study, sponsored by University of California, Los Angeles.
NCT02348814 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02348814 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
Primary Outcome
Date of liver disease diagnosis and estimated duration of disease, listing on liver transplant list, occurrence of liver transplant or re-transplant, presence of cancer (liver-related or otherwise), and death
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-02-26 |
What the finished NCT02348814 record still lists
NCT02348814 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02348814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02348814 about?
NCT02348814 is a clinical study titled "Development of a Novel Biomarker for Liver Fibrosis". The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
What is the current status of trial NCT02348814?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-05. Estimated completion is 2019-02-26.
Who is sponsoring clinical trial NCT02348814?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia